Allogene Therapeutics (ALLO) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($228.6 million vs $217.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | SCTX |
|---|---|---|
| Share price | $0.6277 | $12.07 |
| Market cap | $217.48M | $228.58M |
| 1-day change | -5.88% | -8.70% |
| YTD return | -54.18% | — |
| 1-year return | -48.97% | — |
| 5-year return | -96.51% | — |
| EPS (TTM) | $-0.61 | $-6.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-190.89M | — |
| 52-week high | $4.46 | $39.60 |
| 52-week low | $0.6192 | $12.00 |
| Distance from 52-week high | -85.93% | -69.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +372.25% |
| Average volume | 7.69M | 403.27K |
| Shares outstanding | 346.47M | 18.94M |
| Employees | 150 | 77 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees
ALLO vs SCTX FAQ
Which is bigger, Allogene Therapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $228.58M compared with $217.48M for Allogene Therapeutics (ALLO).
Are Allogene Therapeutics and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.